Gemcitabine and capecitabine for advanced biliary cancer.

ABSTRACT:

Background

Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience.

Methods

Single institution, retrospective study from 2005 to 2015 of ABC treated with gem-cap.

Results

A total of 372 patients with ABC were identified, of whom 227 (61.0%) were treated with chemotherapy. 153 patients (67.4%) received gem-cap, of which 129 (56.8%) received it in the first line. Thirty two point six percent (42/129) were locally advanced, 67.4% (87/129) had metastatic disease, and 18.6% (24/129) received it as adjuvant therapy. Disease sites included 48.8% [63] intrahepatic cholangiocarcinoma (IHCC), 24.0% [31] extrahepatic cholangiocarcinoma (EHCC) a

SUBMITTER: Gabriel E 

PROVIDER: S-EPMC5582046 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature